167 related articles for article (PubMed ID: 37696934)
1. Subsequent female breast cancer risk associated with anthracycline chemotherapy for childhood cancer.
Wang Y; Ronckers CM; van Leeuwen FE; Moskowitz CS; Leisenring W; Armstrong GT; de Vathaire F; Hudson MM; Kuehni CE; Arnold MA; Demoor-Goldschmidt C; Green DM; Henderson TO; Howell RM; Ehrhardt MJ; Neglia JP; Oeffinger KC; van der Pal HJH; Robison LL; Schaapveld M; Turcotte LM; Waespe N; Kremer LCM; Teepen JC;
Nat Med; 2023 Sep; 29(9):2268-2277. PubMed ID: 37696934
[TBL] [Abstract][Full Text] [Related]
2. Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer.
Feijen EA; Leisenring WM; Stratton KL; Ness KK; van der Pal HJ; Caron HN; Armstrong GT; Green DM; Hudson MM; Oeffinger KC; Robison LL; Stovall M; Kremer LC; Chow EJ
J Clin Oncol; 2015 Nov; 33(32):3774-80. PubMed ID: 26304888
[TBL] [Abstract][Full Text] [Related]
3. Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity.
Feijen EAM; Leisenring WM; Stratton KL; Ness KK; van der Pal HJH; van Dalen EC; Armstrong GT; Aune GJ; Green DM; Hudson MM; Loonen J; Oeffinger KC; Robison LL; Yasui Y; Kremer LCM; Chow EJ
JAMA Oncol; 2019 Jun; 5(6):864-871. PubMed ID: 30703192
[TBL] [Abstract][Full Text] [Related]
4. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
5. Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer.
Zaheed M; Wilcken N; Willson ML; O'Connell DL; Goodwin A
Cochrane Database Syst Rev; 2019 Feb; 2(2):CD012873. PubMed ID: 30776132
[TBL] [Abstract][Full Text] [Related]
6. Subsequent Breast Cancer in Female Childhood Cancer Survivors in the St Jude Lifetime Cohort Study (SJLIFE).
Ehrhardt MJ; Howell CR; Hale K; Baassiri MJ; Rodriguez C; Wilson CL; Joshi SS; Lemond TC; Shope S; Howell RM; Wang Z; Srivastava D; Mulrooney DA; Zhang J; Robison LL; Ness KK; Hudson MM
J Clin Oncol; 2019 Jul; 37(19):1647-1656. PubMed ID: 31075046
[TBL] [Abstract][Full Text] [Related]
7. Association of Breast Cancer Risk After Childhood Cancer With Radiation Dose to the Breast and Anthracycline Use: A Report From the Childhood Cancer Survivor Study.
Veiga LH; Curtis RE; Morton LM; Withrow DR; Howell RM; Smith SA; Weathers RE; Oeffinger KC; Moskowitz CS; Henderson TO; Arnold MA; Gibson TM; Leisenring WM; Neglia JP; Turcotte LM; Whitton JA; Robison LL; Armstrong GT; Inskip PD; Berrington de Gonzalez A
JAMA Pediatr; 2019 Dec; 173(12):1171-1179. PubMed ID: 31657853
[TBL] [Abstract][Full Text] [Related]
8. Effect of standard low-dose anthracycline chemotherapy on late congestive heart failure in breast cancer survivors aged between 50 and 59 at diagnosis: A nationwide study.
Chung IY; Lee JW; Moon HG; Shin KH; Han W; Son BH; Ahn SH; Noh DY
Breast; 2020 Oct; 53():125-129. PubMed ID: 32771950
[TBL] [Abstract][Full Text] [Related]
9. Excellent results of screening for subsequent breast cancers in long-term survivors of childhood Hodgkin's lymphoma-Results of a population-based study.
Zadravec Zaletel L; Cesen Mazic M; Jazbec J; Kos G; Toplak M; Štrbac D
Front Pediatr; 2023; 11():1161128. PubMed ID: 37077334
[TBL] [Abstract][Full Text] [Related]
10. Secondary Breast Cancer Risk by Radiation Volume in Women With Hodgkin Lymphoma.
Conway JL; Connors JM; Tyldesley S; Savage KJ; Campbell BA; Zheng YY; Hamm J; Pickles T
Int J Radiat Oncol Biol Phys; 2017 Jan; 97(1):35-41. PubMed ID: 27979454
[TBL] [Abstract][Full Text] [Related]
11. Echocardiographic surveillance for asymptomatic late-onset anthracycline cardiomyopathy in childhood cancer survivors.
Abosoudah I; Greenberg ML; Ness KK; Benson L; Nathan PC
Pediatr Blood Cancer; 2011 Sep; 57(3):467-72. PubMed ID: 21280201
[TBL] [Abstract][Full Text] [Related]
12. Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis.
Batist G; Harris L; Azarnia N; Lee LW; Daza-Ramirez P
Anticancer Drugs; 2006 Jun; 17(5):587-95. PubMed ID: 16702817
[TBL] [Abstract][Full Text] [Related]
13. Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis.
Yamaguchi N; Fujii T; Aoi S; Kozuch PS; Hortobagyi GN; Blum RH
Eur J Cancer; 2015 Nov; 51(16):2314-20. PubMed ID: 26343314
[TBL] [Abstract][Full Text] [Related]
14. Association of Anthracycline With Heart Failure in Patients Treated for Breast Cancer or Lymphoma, 1985-2010.
Larsen CM; Garcia Arango M; Dasari H; Arciniegas Calle M; Adjei E; Rico Mesa J; Scott CG; Thompson CA; Cerhan JR; Haddad TC; Goetz MP; Herrmann J; Villarraga HR
JAMA Netw Open; 2023 Feb; 6(2):e2254669. PubMed ID: 36735254
[TBL] [Abstract][Full Text] [Related]
15. Association of Circulating Cardiomyocyte Cell-Free DNA With Cancer Therapy-Related Cardiac Dysfunction in Patients Undergoing Treatment for ERBB2-Positive Breast Cancer.
Yu AF; Moore ZR; Moskowitz CS; Liu JE; Dang CT; Ramanathan L; Oeffinger KC; Steingart RM; Schmitt AM
JAMA Cardiol; 2023 Jul; 8(7):697-702. PubMed ID: 37256614
[TBL] [Abstract][Full Text] [Related]
16. Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group.
de Baat EC; van Dalen EC; Mulder RL; Hudson MM; Ehrhardt MJ; Engels FK; Feijen EAM; Grotenhuis HB; Leerink JM; Kapusta L; Kaspers GJL; Merkx R; Mertens L; Skinner R; Tissing WJE; de Vathaire F; Nathan PC; Kremer LCM; Mavinkurve-Groothuis AMC; Armenian S
Lancet Child Adolesc Health; 2022 Dec; 6(12):885-894. PubMed ID: 36174614
[TBL] [Abstract][Full Text] [Related]
17. Exposure to anthracyclines during childhood causes cardiac injury.
Lipshultz SE
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
[TBL] [Abstract][Full Text] [Related]
18. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study.
Bowles EJ; Wellman R; Feigelson HS; Onitilo AA; Freedman AN; Delate T; Allen LA; Nekhlyudov L; Goddard KA; Davis RL; Habel LA; Yood MU; McCarty C; Magid DJ; Wagner EH;
J Natl Cancer Inst; 2012 Sep; 104(17):1293-305. PubMed ID: 22949432
[TBL] [Abstract][Full Text] [Related]
19. Comparisons of Cardiotoxicity and Efficacy of Anthracycline-Based Therapies in Breast Cancer: A Network Meta-Analysis of Randomized Clinical Trials.
Mao Z; Shen K; Zhu L; Xu M; Yu F; Xue D; Li H; Xue C
Oncol Res Treat; 2019; 42(7-8):405-413. PubMed ID: 31104059
[TBL] [Abstract][Full Text] [Related]
20. Utilization of Cardiac Surveillance Tests in Survivors of Breast Cancer and Lymphoma After Anthracycline-Based Chemotherapy.
Ruddy KJ; Sangaralingham LR; Van Houten H; Nowsheen S; Sandhu N; Moslehi J; Neuman H; Jemal A; Haddad TC; Blaes AH; Villarraga HR; Thompson C; Shah ND; Herrmann J
Circ Cardiovasc Qual Outcomes; 2020 Mar; 13(3):e005984. PubMed ID: 32106704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
